Silverarc Capital Management’s Trevi Therapeutics TRVI Stock Holding History

Silverarc Capital Management’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.6M	Buy	678,095 +166,968	+33%	+$2.43M	1.31%	25
2026 Q1	$6.1M	Sell	511,127 -30,113	-6%	-$337K	0.62%	38
2025 Q4	$6.78M	Sell	541,240 -47,549	-8%	-$550K	0.94%	29
2025 Q3	$5.39M	Buy	588,789 +49,202	+9%	+$369K	0.73%	36
2025 Q2	$2.95M	Buy	539,587 +9,587	+2%	+$59.6K	0.54%	42
2025 Q1	$3.33M	Sell	530,000 -204,234	-28%	-$974K	0.68%	40
2024 Q4	$3.03M	Buy	734,234 +251,659	+52%	+$806K	0.66%	40
2024 Q3	$1.61M	Sell	482,575 -361,660	-43%	-$1.08M	0.36%	51
2024 Q2	$2.52M	Hold	844,235	–	–	0.59%	45
2024 Q1	$2.91M	Sell	844,235 -19,648	-2%	-$43.8K	0.81%	37
2023 Q4	$1.16M	Sell	863,883 -63,532	-7%	-$96.2K	0.34%	57
2023 Q3	$2.02M	Buy	927,415 +41,491	+5%	+$93.7K	0.61%	45
2023 Q2	$2.12M	Hold	885,924	–	–	0.66%	44
2023 Q1	$1.64M	Buy	885,924 +118,293	+15%	+$268K	0.68%	48
2022 Q4	$1.48M	Sell	767,631 -171,634	-18%	-$338K	0.42%	60
2022 Q3	$1.45M	Buy	+939,265	New	+$3.08M	0.49%	55

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Silverarc Capital Management's TRVI Position: Q2 2026 in Review

Silverarc Capital Management increased its Trevi Therapeutics (TRVI) stake by 33% in Q2 2026, buying an estimated $2.43M and bringing the position to 678,095 shares worth $12.6M. The position accounts for 1.31% of the portfolio, ranked #25.

Silverarc Capital Management first reported a position in TRVI in Q3 2022 and has held it in 16 quarters since. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

Silverarc Capital Management held 678,095 shares of Trevi Therapeutics worth $12.6M as of Q2 2026.
Silverarc Capital Management bought 166,968 Trevi Therapeutics shares in Q2 2026, an estimated $2.43M.
Trevi Therapeutics made up 1.31% of Silverarc Capital Management's portfolio in Q2 2026, its #25 holding.
Silverarc Capital Management first reported a position in Trevi Therapeutics in Q3 2022 and has held it in 16 quarters since.
218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.